Literature DB >> 32132654

Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Adriano Venditti1, Robert Peter Gale2, Francesco Buccisano3, Gert Ossenkoppele4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32132654     DOI： 10.1038/s41375-020-0780-6

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Authors:  Bruno Paiva; María-Belen Vidriales; Amparo Sempere; Fabián Tarín; Enrique Colado; Celina Benavente; María-Teresa Cedena; Joaquín Sánchez; Teresa Caballero-Velazquez; Lourdes Cordón; Juan-Jose Garces; Catia Simoes; David Martínez-Cuadrón; Teresa Bernal; Carmen Botella; Sofia Grille; Josefina Serrano; Carlos Rodríguez-Medina; Lorenzo Algarra; Juan-Manuel Alonso-Domínguez; María-Luz Amigo; Manuel Barrios; Raimundo García-Boyero; Mercedes Colorado; Jaime Pérez-Oteyza; Manuel Pérez-Encinas; Lisette Costilla-Barriga; María-José Sayas; Olga Pérez; Marcos González-Díaz; José A Pérez-Simón; Joaquín Martínez-López; Claudia Sossa; Alberto Orfao; Jesús F San Miguel; Miguel-Ángel Sanz; Pau Montesinos
Journal:  Leukemia       Date:  2021-02-01       Impact factor: 11.528

2.  Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.

Authors:  Michael Heuser; Bennet Heida; Konstantin Büttner; Clara Philine Wienecke; Katrin Teich; Carolin Funke; Maximilian Brandes; Piroska Klement; Alessandro Liebich; Martin Wichmann; Blerina Neziri; Anuhar Chaturvedi; Arnold Kloos; Konstantinos Mintzas; Verena I Gaidzik; Peter Paschka; Lars Bullinger; Walter Fiedler; Albert Heim; Wolfram Puppe; Jürgen Krauter; Konstanze Döhner; Hartmut Döhner; Arnold Ganser; Michael Stadler; Lothar Hambach; Razif Gabdoulline; Felicitas Thol
Journal:  Blood Adv       Date:  2021-05-11

3.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Michael Heuser; Sylvie D Freeman; Gert J Ossenkoppele; Francesco Buccisano; Christopher S Hourigan; Lok Lam Ngai; Jesse M Tettero; Costa Bachas; Constance Baer; Marie-Christine Béné; Veit Bücklein; Anna Czyz; Barbara Denys; Richard Dillon; Michaela Feuring-Buske; Monica L Guzman; Torsten Haferlach; Lina Han; Julia K Herzig; Jeffrey L Jorgensen; Wolfgang Kern; Marina Y Konopleva; Francis Lacombe; Marta Libura; Agata Majchrzak; Luca Maurillo; Yishai Ofran; Jan Philippe; Adriana Plesa; Claude Preudhomme; Farhad Ravandi; Christophe Roumier; Marion Subklewe; Felicitas Thol; Arjan A van de Loosdrecht; Bert A van der Reijden; Adriano Venditti; Agnieszka Wierzbowska; Peter J M Valk; Brent L Wood; Roland B Walter; Christian Thiede; Konstanze Döhner; Gail J Roboz; Jacqueline Cloos
Journal:  Blood       Date:  2021-12-30       Impact factor: 22.113

4.  Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation.

Authors:  Maria Hernandez-Valladares; Elise Aasebø; Frode Berven; Frode Selheim; Øystein Bruserud
Journal:  Aging (Albany NY)       Date:  2020-12-20       Impact factor: 5.682

5.  Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia.

Authors:  Tali Azenkot; Brian A Jonas
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

6.  Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.

Authors:  Sijian Yu; Zhiping Fan; Liping Ma; Yu Wang; Fen Huang; Qing Zhang; Jiafu Huang; Shunqing Wang; Na Xu; Li Xuan; Mujun Xiong; Lijie Han; Zhiqiang Sun; Hongyu Zhang; Hui Liu; Guopan Yu; Pengcheng Shi; Jun Xu; Meiqing Wu; Ziwen Guo; Yiying Xiong; Chongyang Duan; Jing Sun; Qifa Liu; Yu Zhang
Journal:  JAMA Netw Open       Date:  2021-07-01

7.  Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes.

Authors:  Sijian Yu; Tong Lin; Danian Nie; Yu Zhang; Zhiqiang Sun; Qing Zhang; Caixia Wang; Mujun Xiong; Zhiping Fan; Fen Huang; Na Xu; Hui Liu; Guopan Yu; Hongyu Zhang; Pengcheng Shi; Jun Xu; Li Xuan; Ziwen Guo; Meiqing Wu; Lijie Han; Yiying Xiong; Jing Sun; Yu Wang; Qifa Liu
Journal:  Blood Cancer J       Date:  2021-12-06       Impact factor: 11.037
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.